The U.S. Food and Drug Administration (FDA) has officially approved Novartis’ latest gene replacement therapy, Itvisma, marking a significant milestone in the treatment landscape ...
ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...